Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
Status:
Completed
Trial end date:
2019-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when
administered for 29 days in a cross-over design